

ADVENTRX PHARMACEUTICALS INC  
Form 8-K  
June 21, 2012

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

June 20, 2012

ADVENTRX Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-32157

84-1318182

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

12390 El Camino Real, Suite 150, San Diego,  
California

92130

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

858-552-0866

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Top of the Form**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On June 20, 2012, ADVENTRX Pharmaceuticals, Inc. (the Company) held its 2012 Annual Meeting of Stockholders (the Annual Meeting). The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for and against, as well as the number of abstentions and broker non-votes as to each such matter, as applicable.

1. To elect four directors to hold office until the next annual meeting of stockholders and until their successors are elected and qualified or until their earlier resignation or removal:

|                  | <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker<br/>Non-Vote</b> |
|------------------|------------|----------------|----------------|----------------------------|
| <b>Nominee</b>   |            |                |                |                            |
| Brian M. Culley  | 11,904,371 | 647,235        | 219,473        | 22,437,754                 |
| Jack Lief        | 11,534,421 | 1,009,830      | 226,828        | 22,437,754                 |
| David A. Ramsay  | 11,542,279 | 1,005,922      | 222,878        | 22,437,754                 |
| Lewis J. Shuster | 11,538,031 | 1,006,180      | 226,868        | 22,437,754                 |

In accordance with the above results, each nominee was elected to serve as director.

2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2012:

| <b>For</b> | <b>Against</b> | <b>Abstain</b> | <b>Broker<br/>Non-Vote</b> |
|------------|----------------|----------------|----------------------------|
| 34,696,766 | 474,146        | 37,921         | 0                          |

In accordance with the above results, the appointment of PricewaterhouseCoopers LLP was ratified.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVENTRX Pharmaceuticals, Inc.

*June 21, 2012*

By: */s/ Patrick L. Keran*

---

*Name: Patrick L. Keran*

*Title: President and Chief Operating Officer*